EPIRUS Biopharma (EPRS) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
EPIRUS Biopharmaceuticals Reports First Quarter 2015 Financial Results
May 12, 2015 7:00 AM EDTBOSTON, May 12, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced financial results for the first quarter ended March 31, 2015.
"We started the year off by raising close to $53 million from our public offering, enabling us to strengthen our balance sheet and add new long-term shareholders," stated Amit Munshi, President and Chief Executive Officer, EPIRUS... More
EPIRUS Biopharmaceuticals Reports First Quarter 2015 Financial Results
May 12, 2015 7:00 AM EDTBOSTON, May 12, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced financial results for the first quarter ended March 31, 2015.
"We started the year off by raising close to $53 million from our public offering, enabling us to strengthen our balance sheet and add new long-term shareholders," stated Amit Munshi, President and Chief Executive Officer, EPIRUS... More
